{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:50:23Z","timestamp":1793638223455,"version":"4.5.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.dmpk.2026.101525","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:14:46Z","timestamp":1770225286000},"page":"101525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Characterization of drug-drug interaction for antibody-drug conjugates and risk assessment using various approaches including physiologically based pharmacokinetic modeling"],"prefix":"10.1016","volume":"67","author":[{"given":"Dan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Yan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2026.101525_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/mabs.27022","article-title":"Site-specific antibody drug conjugates for cancer therapy","volume":"6","author":"Panowski","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.dmpk.2026.101525_bib2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","article-title":"The antibody-drug conjugate landscape","volume":"23","author":"Flynn","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.dmpk.2026.101525_bib5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00280-020-04054-8","article-title":"Pharmacokinetics of polatuzumab vedotin in combination with R\/G-CHP in patients with B-cell Non-Hodgkin lymphoma","volume":"85","author":"Shemesh","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101525_bib6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11095-020-02933-6","article-title":"Application of a two-analyte integrated population pharmacokinetic model to evaluate the impact of intrinsic and extrinsic factors on the pharmacokinetics of polatuzumab vedotin in patients with non-hodgkin lymphoma","volume":"37","author":"Lu","year":"2020","journal-title":"Pharm Res"},{"key":"10.1016\/j.dmpk.2026.101525_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/psp4.12482","article-title":"Integrated two-analyte population pharmacokinetic model of polatuzumab vedotin in patients with non-Hodgkin lymphoma","volume":"9","author":"Lu","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101525_bib8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/cpt.2448","article-title":"Risk-based pharmacokinetic and drug-drug interaction characterization of antibody-drug conjugates in oncology clinical development: an international consortium for innovation and quality in pharmaceutical development perspective","volume":"112","author":"Li","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2026.101525_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115193","article-title":"Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings","volume":"207","author":"Liao","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.dmpk.2026.101525_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.tpj.6500072","article-title":"UGT1A1\u221728 polymorphism as a determinant of irinotecan disposition and toxicity","volume":"2","author":"Iyer","year":"2002","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.dmpk.2026.101525_bib11","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1124\/dmd.107.017806","article-title":"Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1\u221728 polymorphism","volume":"35","author":"Zhang","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2026.101525_bib12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1124\/dmd.30.4.391","article-title":"Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes","volume":"30","author":"Hanioka","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2026.101525_bib13","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1080\/00498254.2018.1531158","article-title":"Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys","volume":"49","author":"Nagai","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmpk.2026.101525_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.dmpk.2026.101525_bib15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.dmpk.2026.101525_bib16","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1124\/dmd.116.073031","article-title":"Antibody drug conjugates differentiate uptake and DNA alkylation of pyrrolobenzodiazepines in tumors from organs of xenograft mice","volume":"44","author":"Ma","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2026.101525_bib17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/dmd.120.090878","article-title":"NADPH-independent inactivation of CYP2B6 and NADPH-dependent inactivation of CYP3A4\/5 by PBD: potential implication for assessing covalent modulators for time-dependent inhibition","volume":"48","author":"Kosaka","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2026.101525_bib18","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1124\/dmd.112.046169","article-title":"In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates","volume":"40","author":"Davis","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2026.101525_bib19","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S1471-4892(03)00083-3","article-title":"Antibody-targeted chemotherapy with immunoconjugates of calicheamicin","volume":"3","author":"Damle","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101525_bib20","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dmpk.2026.101525_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/1872312809666150602151922","article-title":"Non-clinical disposition and metabolism of DM1, a component of trastuzumab emtansine (T-DM1), in Sprague Dawley rats","volume":"9","author":"Shen","year":"2015","journal-title":"Drug Metabol Lett"},{"key":"10.1016\/j.dmpk.2026.101525_bib22","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2174\/138920012802138598","article-title":"Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism","volume":"13","author":"Shen","year":"2012","journal-title":"Curr Drug Metabol"},{"key":"10.1016\/j.dmpk.2026.101525_bib23","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/ajhp\/zxaf011","article-title":"A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer","volume":"82","author":"Smith","year":"2025","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.dmpk.2026.101525_bib24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/cpt.3102","article-title":"Prediction of CYP down regulation after tusamitamab ravtansine administration (a DM4-conjugate), based on an in vitro-in vivo extrapolation approach","volume":"115","author":"Pouzin","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2026.101525_bib25","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/psp4.12769","article-title":"Covariate analysis of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate, based on first-in-human study","volume":"11","author":"Pouzin","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101525_bib26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0090-9556(24)15060-X","article-title":"Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients","volume":"28","author":"Slatter","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2026.101525_bib27","first-page":"2747","article-title":"Irinotecan (CPT-11) metabolism and disposition in cancer patients","volume":"4","author":"Sparreboom","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dmpk.2026.101525_bib28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s002800050656","article-title":"Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice","volume":"40","author":"Stewart","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101525_bib29","doi-asserted-by":"crossref","first-page":"17574","DOI":"10.1021\/acs.jmedchem.5c01251","article-title":"Property-based prediction uncovers intestinal excretion as an elimination route of small-molecule drugs","volume":"68","author":"Chen","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.dmpk.2026.101525_bib30","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40262-018-0644-7","article-title":"Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics","volume":"57","author":"de Man","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2026.101525_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2024.101001","article-title":"Unveiling the intra-tumor fate of trastuzumab deruxtecan in a xenograft model to support its mechanism of action","volume":"56","author":"Nagai","year":"2024","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.dmpk.2026.101525_bib32","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1158\/1078-0432.CCR-25-1388","article-title":"FDA approval summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer","volume":"31","author":"Royce","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dmpk.2026.101525_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jpha.2020.05.011","article-title":"Quantitation of DNA by nuclease P1 digestion and UPLC-MS\/MS to assess binding efficiency of pyrrolobenzodiazepine","volume":"10","author":"Ma","year":"2020","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.dmpk.2026.101525_bib34","article-title":"Clinical pharmacology considerations for human radiolabeled mass balance studies","year":"2024","journal-title":"Guidance for Industry"},{"key":"10.1016\/j.dmpk.2026.101525_bib35","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/bcp.12988","article-title":"Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment","volume":"82","author":"Zhao","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101525_bib36","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/jcph.116","article-title":"CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies","volume":"53","author":"Han","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101525_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40262-014-0182-x","article-title":"Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates","volume":"54","author":"Chen","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"10.1016\/j.dmpk.2026.101525_bib38","first-page":"S120","article-title":"Physiologically based pharmacokinetic model-informed drug development for Polatuzumab vedotin: label for drug-drug interactions without dedicated clinical trials","volume":"60","author":"Samineni","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101525_bib39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10928-023-09877-5","article-title":"Physiologically based pharmacokinetic model to predict drug-drug interactions with the antibody-drug conjugate enfortumab vedotin","volume":"51","author":"Choules","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.dmpk.2026.101525_bib40","series-title":"Multi-discipline review: application number 761208Orig1s000 (Tivdak)","year":"2021"},{"key":"10.1016\/j.dmpk.2026.101525_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.70108","article-title":"Assessment of telisotuzumab vedotin drug-drug interaction potential using physiologically-based pharmacokinetic modeling and simulations","author":"Riad","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101525_bib42","unstructured":"761158Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology review."},{"key":"10.1016\/j.dmpk.2026.101525_bib43","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1158\/1078-0432.CCR-21-1560","article-title":"Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan with concomitant ritonavir or itraconazole in patients with HER2-expressing advanced solid tumors","volume":"27","author":"Takahashi","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dmpk.2026.101525_bib44","series-title":"761394Orig1s000MultidisciplineR","year":"2025"},{"key":"10.1016\/j.dmpk.2026.101525_bib45","unstructured":"BLA 761115 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology review."},{"key":"10.1016\/j.dmpk.2026.101525_bib46","series-title":"Clinical Pharmacology review","year":"2021"},{"key":"10.1016\/j.dmpk.2026.101525_bib47","series-title":"Clinical Pharmacology review","year":"2018"},{"key":"10.1016\/j.dmpk.2026.101525_bib49","unstructured":"761060Orig1s000Orig1Orig2s000ClinPharmR gemtuzumab ozogamicin CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) CENTER FOR DRUG EVALUATION AND RESEARCH https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761060Orig1s000Orig1Orig2s000ClinPharmR.pdfn.d."}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134743672600011X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134743672600011X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:17:02Z","timestamp":1774250222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S134743672600011X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":46,"alternative-id":["S134743672600011X"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2026.101525","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of drug-drug interaction for antibody-drug conjugates and risk assessment using various approaches including physiologically based pharmacokinetic modeling","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2026.101525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101525"}}